Reply to: "Monitoring antivitamin K anticoagulants in antiphospholipid syndrome: A challenge in quality"

Atherosclerosis. 2017 Jan:256:148-149. doi: 10.1016/j.atherosclerosis.2016.11.014. Epub 2016 Nov 16.

Authors

Daniele Pastori¹, Sandro Parrotto¹, Tommasa Vicario¹, Mirella Saliola¹, Ivano Mezzaroma², Francesco Violi¹, Pasquale Pignatelli³

Affiliations

¹ I Clinica Medica, Department of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy.
² Department of Clinical Medicine, "Sapienza" University of Rome, Rome, Italy.
³ I Clinica Medica, Department of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy. Electronic address: pasquale.pignatelli@uniroma1.it.

PMID: 27993386
DOI: 10.1016/j.atherosclerosis.2016.11.014

No abstract available

Keywords: Anticoagulant therapy; Antiphospholipid syndrome.

Publication types

Letter
Comment

MeSH terms

Antibodies, Antiphospholipid
Anticoagulants*
Antiphospholipid Syndrome*
Humans
Vitamin K

Substances

Antibodies, Antiphospholipid
Anticoagulants
Vitamin K